Committee Composition

  Audit Nominating and Governance Compensation
Jack Goldstein, Ph.D Chairman of the Board Member of Audit Committee Member of Nominating and Governance Committee Member of Compensation Committee
Scott Cormack      
Neil James Clendeninn, Ph.D, MD   Member of Nominating and Governance Committee Committee Chair for Compensation Committee

Dr. Clendeninn is currently a practicing physician and serves as Program Director for Palliative Medicine Partners: Complex Illness Coordination, a program of Kauai Hospice in Kauai, Hawaii. Dr. Clendeninn has more than 25 years of pharmaceutical industry and clinical experience. He also recently served as Senior Vice-President and Chief Medical Officer of Heron Therapeutics from 2015 to 2016. He is also active in clinical development consulting for the biopharmaceutical industry. Previously, Dr. Clendenin served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from 1993 until his retirement in 2001. With Agouron, Dr. Clendeninn was responsible for development and growth of the Clinical Affairs Department from pre-clinical to phase IV. He and his team were responsible for the rapid development and delivery to market of Viracept, an HIV Protease Inhibitor. Under his leadership, the department grew to over 200 MDs, PhDs, clinical pharmacologists, biostatisticans, data management and a post-marketing medical team. Previous to Agouron, Dr. Clendeninn served as Director of the Clinical Oncology Department for Burroughs Wellcome Company. His other past positions include assistant clinical professor in oncology at the University of North Carolina, senior staff member at the National Cancer Institute, Board of Scientific Advisors of the National Cancer Institute and other general practice and academic-based positions. Dr. Clendeninn has led extensive research in areas that include chemotherapeutic multi-drug resistance, opiate receptors and photochemistry. He has written and co-authored numerous publications and has been an editor of several textbooks. Dr. Clendeninn currently serves on the Boards of OncoGenex Technologies Inc. and OncoGenex Pharmaceuticals. Dr. Clendeninn holds a BA Biology/Chemistry from Wesleyan University, CT, and a PhD Microbiology/Pharmacology and MD from New York University, NY. He completed an Internal Medicine residency at University of Washington, and an Oncology fellowship and post-doc at NCI, NIH in Bethesda, MD.

Martin Mattingly, PharmD Member of Audit Committee   Member of Compensation Committee
Stewart Parker Member of Audit Committee Committee Chair for Nominating and Governance Committee  
David Smith Committee Chair for Audit Committee Member of Nominating and Governance Committee  
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member